Nasal Solution

In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells which occurs after exposure to specific antigens. Cromolyn sodium inhibits the release of histamine and SRS-A (the slow-acting substance of anaphylaxis). Rhinitis induced by the inhalation of specific antigens can be inhibited to varying degrees by pretreatment with cromolyn sodium nasal solution.

Another activity demonstrated in vitrois the capacity of cromolyn sodium to inhibit the degranulation of non-sensitized rat mast cells by phospholipase A and the subsequent release of chemical mediators. An additional in vitro study showed that cromolyn sodium did not inhibit the enzymatic activity of released phospholipase A on its specific substrate.

Cromolyn sodium has no intrinsic bronchodilator, antihistaminic or anti-inflammatory activity.

Cromolyn sodium is poorly absorbed from the gastrointestinal tract. After instillation of cromolyn sodium nasal solution, less than 7% of the total dose administered is absorbed and is rapidly excreted unchanged in the bile and urine. The remainder of the dose is expelled from the nose, or swallowed and excreted via the alimentary tract.

Last reviewed on RxList: 4/28/2008
This monograph has been modified to include the generic and brand name in many instances.